Medimetriks Pharmaceuticals

Executive Summary

Medimetriks Pharmaceuticals is a US-based specialty pharmaceutical company dedicated to developing and commercializing dermatology products. Founded in 2005 and headquartered in Fair Lawn, New Jersey, the company focuses on small molecule therapeutics targeting common and chronic skin conditions. With a robust portfolio of topical treatments, Medimetriks has established itself as a player in the dermatology space, though it remains a private entity without publicly traded shares. The company's strategy appears centered on leveraging existing products and advancing pipeline candidates to address unmet medical needs in dermatology. While specific financials and pipeline details are not publicly disclosed, the company benefits from a focused therapeutic area with consistent demand. Key strengths include a proven ability to commercialize products and a targeted approach to niche markets.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of new topical formulation for psoriasis or eczema60% success
• Q4 2026Strategic partnership or licensing deal for a late-stage dermatology asset55% success
• Q1 2027Positive Phase 2/3 clinical trial results for a lead candidate50% success